Aviso Financial Inc. Has $4.83 Million Position in Abbott Laboratories $ABT

Aviso Financial Inc. grew its position in shares of Abbott Laboratories (NYSE:ABT) by 7.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,476 shares of the healthcare product maker’s stock after purchasing an additional 2,470 shares during the quarter. Aviso Financial Inc.’s holdings in Abbott Laboratories were worth $4,825,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ABT. Brighton Jones LLC increased its holdings in Abbott Laboratories by 10.1% in the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Abbott Laboratories in the first quarter valued at about $245,000. Inspire Advisors LLC bought a new position in shares of Abbott Laboratories during the first quarter worth about $224,000. LPL Financial LLC lifted its stake in shares of Abbott Laboratories by 10.1% in the first quarter. LPL Financial LLC now owns 1,776,882 shares of the healthcare product maker’s stock worth $235,703,000 after acquiring an additional 162,282 shares during the period. Finally, TCW Group Inc. boosted its holdings in Abbott Laboratories by 4.9% in the first quarter. TCW Group Inc. now owns 26,206 shares of the healthcare product maker’s stock valued at $3,476,000 after acquiring an additional 1,218 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.5%

Shares of NYSE ABT opened at $127.44 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The company has a 50-day moving average price of $129.87 and a 200-day moving average price of $131.14. The stock has a market capitalization of $221.61 billion, a P/E ratio of 15.97, a P/E/G ratio of 2.36 and a beta of 0.68. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. The business had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend was Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Analyst Ratings Changes

ABT has been the topic of a number of recent analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of Abbott Laboratories in a research report on Wednesday, October 8th. Benchmark initiated coverage on shares of Abbott Laboratories in a report on Friday, October 10th. They issued a “buy” rating and a $145.00 target price on the stock. Mizuho increased their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Royal Bank Of Canada reissued an “outperform” rating and issued a $147.00 price objective on shares of Abbott Laboratories in a research note on Thursday, October 16th. Finally, BTIG Research reaffirmed a “buy” rating and set a $145.00 target price on shares of Abbott Laboratories in a research note on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $147.00.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.